Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells
Open Access
- 1 June 2004
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (24) , 25345-25352
- https://doi.org/10.1074/jbc.m400590200
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Specific Targeted Therapy of Chronic Myelogenous Leukemia with ImatinibPharmacological Reviews, 2003
- Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular TherapeuticsAnnals of Internal Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib alone and in combination for chronic myeloid leukemiaSeminars in Hematology, 2003
- STI571: A Paradigm of New Agents for Cancer TherapeuticsJournal of Clinical Oncology, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Structural organization of the bcr gene and its role in the Ph′ translocationNature, 1985
- Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell, 1984